HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oral Contraceptive Rx-to-OTC Switch On The Cusp In UK

Executive Summary

The MHRA is consulting on two Rx-to-OTC switch applications for progestogen-only contraceptive pills containing desogestrel, one from HRA Pharma and one from Maxwellia. The move has been welcomed by UK consumer healthcare industry association, the PAGB, as well as the British Pregnancy Advisory Service. 

You may also be interested in...

Sanofi’s Nasacort Hay Fever Spray Latest In Post-Brexit UK Switch Boom

Sanofi's Nasacort Allergy Relief hay fever spray is the latest in a flood of reclassifications in the UK since the beginning of the year when the country left the European Union.

Maxwellia Poised To Become Consumer Health Player If Daily Contraceptive Switch Approved

Maxwellia is ready to market its Lovima daily contraceptive as a non-prescription brand if its application to switch the progestogen-only pill (POP) in the UK is approved, representing a leap forward for the company. CEO Anna Maxwell tells HBW Insight about Maxwellia's journey from R&D start-up to consumer health player. 

'Hopeful' HRA Pharma Hires Brands2Life To Market OTC Daily Contraceptive In UK

On International Women's Day, we post an update from HRA Pharma, which has appointed Brands2Life to promote the firm's Hana daily contraceptive as a non-prescription medicine in the UK, should the Rx-to-OTC switch currently under consideration be successful. 

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts